Glaukos Corp (GKOS)
Gross profit margin
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gross profit (ttm) | US$ in thousands | 239,136 | 229,667 | 224,537 | 219,093 | 213,883 | 216,253 | 221,185 | 226,667 | 227,384 | 224,653 | 212,212 | 161,768 | 133,240 | 129,541 | 133,448 | 174,288 | 198,396 | 195,409 | 182,500 | 168,771 |
Revenue (ttm) | US$ in thousands | 303,223 | 293,554 | 286,692 | 278,963 | 272,731 | 274,744 | 281,666 | 290,488 | 292,910 | 292,904 | 283,025 | 236,490 | 222,935 | 215,550 | 208,628 | 235,970 | 236,597 | 224,824 | 210,423 | 192,784 |
Gross profit margin | 78.86% | 78.24% | 78.32% | 78.54% | 78.42% | 78.71% | 78.53% | 78.03% | 77.63% | 76.70% | 74.98% | 68.40% | 59.77% | 60.10% | 63.96% | 73.86% | 83.85% | 86.92% | 86.73% | 87.54% |
December 31, 2023 calculation
Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $239,136K ÷ $303,223K
= 78.86%
The gross profit margin of Glaukos Corporation has shown relatively stable performance over the past eight quarters. The margins have consistently remained high, ranging from 75.61% to 77.17%. This indicates that the company is effectively controlling its production and direct costs related to sales. Despite minor fluctuations, the overall trend suggests a strong ability to generate profits from its core business operations. It is essential for Glaukos to continue monitoring and optimizing its cost structure to sustain and potentially improve its gross profit margin in the future.
Peer comparison
Dec 31, 2023
Company name
Symbol
Gross profit margin
Glaukos Corp
GKOS
78.86%
3M Company
MMM
43.46%
Artivion Inc
AORT
69.22%
Baxter International Inc
BAX
33.34%
Becton Dickinson and Company
BDX
5.19%
Boston Scientific Corp
BSX
70.82%
DexCom Inc
DXCM
63.52%
Embecta Corp
EMBC
66.89%
Globus Medical
GMED
65.05%
Haemonetics Corporation
HAE
26.64%
ICU Medical Inc
ICUI
32.75%